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Background: Health care-associated pneumonia (HCAP) includes a broad range of patients
having frequent or chronic contact with health care systems. However, the relationship
between current defining criteria for HCAP and the risk of potentially drug-resistant (PDR)
pathogens is controversial.
Methods: We retrospectively evaluated patients admitted to Severance Hospital in South Kor-
ea with culture-positive pneumonia from January 2008 to December 2009. We analyzed the
associations between risk factors for HCAP and infection with PDR pathogens, and developed
a new scoring system to predict infection with PDR pathogens.
Results: Among 339 patients, PDR pathogens were observed in 122 (36.0%). PDR pathogens
were more common in HCAP than community-acquired pneumonia (CAP) (48.5% versus
23.8%, P< 0.001). In a logistic regression, prior hospitalization within 90 days of pneumonia
(ORZ 2.51, PZ 0.003), recent treatment with antimicrobials (ORZ 2.35, PZ 0.039), and
nasogastric tube feeding (ORZ 15.28, P< 0.001) were independently associated with PDR
pathogens. For the prediction of PDR pathogens, the sensitivity and specificity of current HCAP
criteria were 66.4% and 60.4%, respectively, and 68.0% and 67.3%, respectively, for the new
scoring system. Moreover, the new scoring system showed better diagnostic accuracy than
current HCAP criteria (area under curveZ 0.711 versus 0.634, P< 0.001).
Conclusions: The current HCAP criteria are poor predictors of PDR pathogens and all patients
with HCAP should not be empirically treated for these pathogens. To avoid excessive antibiotic
use, individual risk stratification approaches should be considered.
ª 2012 Elsevier Ltd. All rights reserved.238 2576; fax: þ82 2 393 6884.
(J.Y. Jung).
2 Elsevier Ltd. All rights reserved.
1312 S.C. Park et al.Introduction DefinitionsIn 2005, health care-associated pneumonia (HCAP) was
introduced as a new pneumonia category by the Amer-
ican Thoracic Society (ATS) and the Infectious Disease
Society of America (IDSA).1 ATSeIDSA guidelines define
HCAP as pneumonia occurring in a patient who has been
recently hospitalized, is admitted from a nursing home
or long-term care facility, was recently treated with
infusion therapy or wound care, or needs chronic
dialysis.1
Recent studies reported the characteristics of HCAP.
Patients with HCAP present with more severe disease and
have worse clinical outcomes.2e6 Moreover, they have
higher frequencies of infection with drug-resistant patho-
gens than patients with community-acquired pneumonia
(CAP).2e6 Therefore, current guidelines recommend that
initial broad-spectrum antibiotics should be considered for
treatment of HCAP.1
The incidence and microbiology of HCAP vary among
studies.2e6 Although patients with HCAP have a greater risk
for infection with drug-resistant pathogens, significant
numbers of these patients have pneumonia due to non-
resistant pathogens. The empirical use of antibiotics for
drug-resistant pathogens in patients with HCAP may
increase overtreatment, so it is important to identify which
HCAP patients are more likely to be infected by drug-
resistant pathogens.
The purpose of this study was to identify novel risk
factors for potentially drug-resistant (PDR) pathogens
among patients admitted with pneumonia contracted
outside of the hospital, and to compare risk factors for PDR
pathogens with HCAP criteria. We also evaluated the
accuracy of a new scoring tool using these risk factors and
compared this new system to the currently accepted HCAP
criteria in identifying infection probability with PDR
pathogens.Methods
Study design and subjects
We conducted retrospective observational study on 339
adult (aged> 20 years) patients admitted with culture-
positive pneumonia at Severance Hospital (Yonsei Univer-
sity affiliated tertiary hospital) in South Korea from January
2008 to December 2009. Patients were classified into either
PDR or non-PDR groups. The PDR group included those with
methicillin-resistant Staphylococcus aureus (MRSA), Pseu-
domonas aeruginosa, Acinetobacter baumannii,
Stenotrophomonas maltophilia, and extended-spectrum b-
lactamase (ESBL)-producing Enterobacteriaceae, based on
previous reports showing poor clinical outcomes in patients
infected with these pathogens.7,8 We compared baseline
characteristics and treatment outcomes between PDR and
non-PDR groups, and identified risk factors for PDR path-
ogen infection. We also created a new scoring tool and
evaluated its diagnostic accuracy in predicting infection
with PDR pathogens. This study protocol was approved by
the Ethical Review Committee of Severance Hospital.Pneumonia was defined as the presence of a new infiltrate
on chest radiograms with at least one of the following
symptoms: fever or hypothermia, cough with or without
sputum, chest pain, dyspnea, or altered breath sounds on
auscultation.9
HCAP was defined by at least one of the following
criteria: hospitalization within 90 days before pneumonia
diagnosis; admission from a nursing home or a long-term
care facility; infusion therapy such as intravenous antibi-
otics, chemotherapy or wound care within 30 days before
pneumonia diagnosis; and/or chronic hemodialysis or peri-
toneal dialysis.1
We defined immunosuppressed patients as those in at
least one of following categories: daily treatment with
systemic corticosteroids (15 mg of prednisone/day for
more than 1 month) or combination therapy with low-dose
corticosteroids and other immunosuppressants (azathio-
prine, mycophenolate, methotrexate, cyclosporine, or
cyclophosphamide); seropositivity for human immunodefi-
ciency virus; receipt of either solid organ or bone marrow
transplants; radiation therapy or chemotherapy for an
underlying malignancy within 6 months prior to hospital
admission; or diagnosis with an underlying acquired
immune deficiency disorder.4,10
Inappropriate antibiotic therapy was defined as when
initially prescribed antibiotics were not active against the
identified pathogens. Overtreatment was defined as when
narrow-specificity antibiotics active against the identified
pathogens, based on in vitro susceptibility testing, were
available, but other antibiotics were initially
prescribed.3,5Microbiological studies and antibiotic treatment
Pathogens from sputum, blood, or other samples were
investigated using standard microbiological procedures.
Blood cultures were considered as an etiological diagnosis
if there was no other infection source for the positive
blood culture. Sputum samples were cultured using
semi-quantitative manner and an etiological diagnosis was
confirmed when a predominant microorganism was
isolated from group 5 sputum, according to Murray and
Washington’s grading system.11 Positive cultures of pleural
or bronchoalveolar lavage fluid were considered as the
etiology. Positive urine antigen for either Streptococcus
pneumoniae or Legionella was considered evidence of
bacterial infection. Antibodies against atypical pathogens
such as Mycoplasma pneumoniae were considered
evidence of infection. Aspergillus species were considered
as an etiology when Aspergillus species were confirmed by
histopathology or when the following three criteria were
met: no other organism was identified; Aspergillus
galactomannan antigen assay was positive in serum or
body fluid such as pleural or bronchoalveolar lavage fluid;
and pneumonia was improved after anti-fungal therapy.12
Antibiotic therapy was initiated according to ATS/IDSA
guidelines, and was modulated after the pathogen was
identified by susceptibility tests.1,13 Sometimes, however,
HCAP and PDR pathogens 1313antibiotic selection was changed according to
the attending physician’s decision, taking into
consideration individual patient’s risk factors and disease
severity.Statistics
We conducted univariate analyses with c2 test or the Fisher
exact test for categorical variables and Student t test or
ManneWhitney U test for continuous variables. To identify
risk factors independently associated with PDR pathogen
occurrence, we conducted multivariate analysis using
a logistic regression model. Potential explanatory variables
were those found significant in univariate analysis, and
those considered to be significant risk factors in previous
studies. Multi-collineartiy of these variables was checked,
and goodness-of-fit of the model was verified by the Hos-
mereLemeshow test. All tests were two-sided, and a P-
value< 0.05 was deemed statistically significant. From
logistic regression results we created a new scoring system
to predict patients’ risk for infection with PDR pathogens.
We converted the odd radios (ORs) from b coefficients into
point values and measured the percentages of PDR patho-
gens in each group relative to the total point score. We
then evaluated the ability of the new scoring system to
predict patients with PDR pathogens using the receiver
operating characteristic (ROC) curve.Table 1 Baseline characteristics of pneumonia patients with PD
Baseline characteristics PDR
(nZ 122)
Age, yr 65.6 12.8
Male 80 (65.6)
Female 42 (34.4)
Type of pneumonia
Community-acquired 41 (33.6)
Health care associated 81 (66.4)
Underlying diseases
Diabetes mellitus 32 (26.2)
Chronic lung diseaseb 22 (18.0)
Cerebral vascular accident 36 (29.5)
Renal disease 17 (13.9)
Hypertension 61 (50.0)
Cardiovascular disease 15 (12.3)
Liver disease 3 (2.5)
Rheumatologic disease 5 (4.1)
Malignancy 48 (39.3)
Clinical parameters
Confusion 25 (20.5)
Septic shock at onset 37 (30.3)
PaO2< 60 mmHg, SpO2
< 90%, or PaO2/FiO2< 300
35 (32.1)
Acute renal failure at onset 26 (21.3)
Immunosuppression 37 (30.3)
PDR, potentially drug-resistant.
a Data are presented as numbers (percentages), and as means sta
b Chronic lung disease includes asthma, chronic obstructive pulmona
interstitial lung disease.Results
Baseline characteristics of pneumonia patients
infected with PDR and non-PDR pathogens
Of the 339 patients, PDR pathogens were identified in 122
(36.0%) and non-PDR pathogens in 217 (64.0%). Baseline
characteristics of patients with PDR and non-PDR pathogens
are shown in Table 1. There were 172 (50.7%) patients with
CAP and 167 (49.3%) patients with HCAP. Of the 122 PDR
patients, 41 (33.6%) had CAP and 81 (66.4%) had HCAP.
Although HCAP was more common than CAP in patients
infected with PDR pathogens, relatively larger numbers of
patients with HCAP (51.5%) had non-PDR pathogens. Cere-
bral vascular accident as underlying disease and confusion
status at the time of admission were more prevalent in
patients with PDR pathogens. However, other underlying
diseases and clinical parameters showed no differences
between the two groups.Distribution of identified pathogens
Table 2 shows organisms isolated in patients with CAP and
HCAP. S. pneumoniae (32.0%), Klebsiella pneumoniae
(15.1%), and M. pneumoniae (15.1%) were most commonly
isolated in patients with CAP, while K. pneumoniae (26.9%),R and non-PDR.a
Non-PDR P-value
(nZ 217)
66.9 14.4 0.412
153 (70.5) 0.347
64 (29.5)
131 (60.4) <0.001
86 (39.6)
49 (22.6) 0.450
41 (18.9) 0.845
36 (16.6) 0.005
19 (8.8) 0.137
90 (41.5) 0.130
34 (15.7) 0.397
9 (4.1) 0.548
7 (3.2) 0.762
84 (38.7) 0.908
24 (11.1) 0.018
46 (21.2) 0.061
65 (32.7) 0.921
44 (20.3) 0.821
53 (24.4) 0.237
ndard deviation, unless otherwise indicated.
ry disease, and structural lung diseases such as bronchiectasis and
Table 2 Distribution of isolated pathogens in CAP and HCAP patients.a
Microbes CAP HCAP P-value
(nZ 172)b (nZ 167)b
Gram-positive pathogens
MRSA 9 (5.2) 18 (10.8) 0.059
MSSA 15 (8.7) 11 (6.6) e
Streptococcus pneumoniae 55 (32.0) 22 (13.2) <0.001
Gram-negative pathogens
Pseudomonas aeruginosa 23 (13.4) 35 (21.0) 0.064
Escherichia coli 2 (1.2) 5 (3.0) e
Haemophilus influenzae 4 (2.3) 2 (1.2) e
Klebsiella pneumoniae 26 (15.1) 45 (26.9) 0.007
Enterobacter species 4 (2.3) 9 (5.4) e
Acinetobacter baumannii 1 (0.6) 4 (2.4) e
Stenotrophomonas maltophilia 2 (1.2) 2 (1.2) e
Others 10 (5.8)c 12 (7.2)d e
Atypical pathogens
Mycoplasma pneumoniae 26 (15.1) 5 (3.0) <0.001
Legionella pneumophila 1 (0.6) 0 (0) e
Fungal pathogens 1 (0.6)e 1 (0.6)e e
CAP, community-acquired pneumonia; HCAP, health care-associated pneumonia; MRSA, methicillin-resistant Staphylococcus aureus;
MSSA, methicillin-sensitive Staphylococcus aureus.
a Data are presented as numbers (percentages).
b The total number of isolated pathogens is different from the number of patients due to multiple pathogens isolated in 7 CAP
patients (4.1%) and 4 HCAP patients (2.4%).
c Moraxella catarrhalis (nZ 6), Serratia marcescens (nZ 3), Enterococcus faecalis (nZ 1).
d Moraxella catarrhalis (nZ 4), Serratia marcescens (nZ 3), Bacteroides fragilis (nZ 1), Citrobacter species (nZ 2), Morganella
morganii (nZ 2).
e Aspergillus species.
1314 S.C. Park et al.P. aeruginosa (21.0%), S. pneumoniae (13.2%) were common
in patients with HCAP.
Antibiotic treatment and clinical outcomes
Antibiotic regimens and treatment results of patients with
either PDR or non-PDR pathogens are shown in Table 3. Both
patient groups initially received combination antibiotic
therapy more often than monotherapy. The most common
antibiotic combinations were anti-pseudomonal b-lactams
plus fluoroquinolone in patients with PDR pathogens and b-
lactams plus macrolide or anti-pseudomonal b-lactams plus
fluoroquinolone in patients with non-PDR pathogens. Inap-
propriate antibiotic therapy was more frequent in patients
with PDR pathogens versus non-PDR pathogens, but no
difference was found in the frequency of inappropriate
antibiotic therapy between the patients with CAP and
HCAP. Overtreatment in the patients with non-PDR patho-
gens was more frequent in the HCAP group than in the CAP
group (61.6% versus 35.1%, P< 0.001). Table 4 shows
disease severity and clinical outcomes in CAP and HCAP
patients. Patients with HCAP have higher Pneumonia
Severity Index scores and in-hospital mortality than those
with CAP.
Association of HCAP risk factors and PDR pathogens
Table 5 shows the multivariate analysis of the seven risk
factors of HCAP that were previously reported, as well asnasogastric tube feeding, included as a novel risk factor in
this study. Of the HCAP risk factors, recent hospitalization
(41.9%), immunosuppression (26.5%), recent antibiotic
treatment (13.6%), and recent chemotherapy (13.6%) were
common in the order of frequency. Three variables were
independently associated with the identification of patients
with PDR pathogens: recent hospitalization within 90 days
of the pneumonia (odds ratio [OR]Z 2.51; 95% confidence
interval [CI], 1.36e4.63; PZ 0.003), intravenous antibi-
otics within 30 days of pneumonia (ORZ 2.35; 95% CI,
1.04e5.29; PZ 0.039), and nasogastric tube feeding
(ORZ 15.28; 95% CI, 4.15e56.28; P< 0.001). The model
had a good fit, as indicated by HosmereLemeshow test
(PZ 0.803). Fig. 1 shows the percentages of PDR pathogens
in each patient group with different numbers of risk factors
for HCAP. No patient had more than three risk factors for
HCAP in this study. As the number of risk factors for HCAP
increased, the percentage of infection with PDR pathogens
also increased (P< 0.01 for trend). The sensitivity, speci-
ficity, positive predictive value (PPV), and negative
predictive value (NPV) of current HCAP criteria were 66.4%
(95% CI, 59.0e73.3), 60.4% (95% CI, 56.2e64.2), 48.5% (95%
CI, 43.1e53.5) and 76.2% (95% CI, 70.9e81.0), respectively.New scoring system
Based on the multivariate analysis of the association
between risk factors of HCAP and PDR pathogens, we
created a new scoring system to identify patients infected
Table 3 Antibiotic treatment of pneumonia patients with PDR and non-PDR pathogens.a
Treatment PDR Non-PDR P-value
(nZ 122) (nZ 217)
Monotherapy 25 (20.5) 49 (22.6) 0.655
Amino-penicillins 2 (1.6) 7 (3.2) e
Cephalosporin 2 (1.6) 7 (3.2) e
Anti-pseudomonal penicillins 4 (3.3) 10 (4.6) e
Fluoroquinolone 12 (9.8) 25 (11.5) e
Carbapenem 5 (4.1) 0 (0) 0.006
Combination therapy 97 (79.5) 168 (77.4) 0.655
b-lactamsþ fluoroquinolone 3 (2.5) 11 (5.1) e
b-lactamsþmacrolide 14 (11.5) 56 (25.8) 0.002
b-lactamsþ clindamycin 7 (5.7) 9 (4.1) e
b-lactamsþ aminoglycoside 8 (6.6) 9 (4.1) e
Fluoroquinoloneþ clindamycin 2 (1.6) 5 (2.3) e
Anti-pseudomonal
b-lactamsþ fluoroquinolone
40 (32.8) 56 (25.8) e
Anti-pseudomonal
b-lactamsþmacrolide
1 (0.8) 0 (0) e
Anti-pseudomonal
b-lactamsþ clindamycin
3 (2.5) 3 (1.4) e
Anti-pseudomonal
b-lactamsþ aminoglycoside
4 (3.3) 4 (1.8) e
Other combination therapyb 6 (4.9) 5 (2.3) e
Combination therapy including
glycopeptides
9 (7.4) 10 (4.6) e
Inappropriate antibiotic therapy 66 (54.1) 3 (1.4) <0.001
Community-acquired 20/41 (48.8) 2/131 (1.5) <0.001
Health care-associated 46/81 (56.8) 1/86 (1.2) <0.001
Overtreatment 8 (6.6) 99 (45.6) <0.001
Community-acquired 3/41 (7.3) 46/131 (35.1)c <0.001
Health care-associated 5/81 (6.2) 53/86 (61.6)c <0.001
PDR, potentially drug-resistant; ICU, intensive care unit.
a Data are presented as numbers (percentages).
b Others contain combination therapy of three or more drugs except glycopeptide.
c P< 0.001.
Table 4 Disease severity and clinical outcomes in CAP and
HCAP patients.a
Treatment CAP HCAP P-value
(nZ 172) (nZ 167)
Disease severity
CURB65 1.6 1.2 1.7 1.1 0.349
Pneumonia
Severity Index
101.3 40.7 116.3 31.6 <0.001
Clinical outcomes
In-hospital
mortality
27 (15.7) 47 (28.1) 0.006
ICU admission 46 (26.7) 47 (28.1) 0.773
Duration of
hospital stay
(days)
20.3 29.2 24.2 37.9 0.289
CAP, community-acquired pneumonia; HCAP, health care-
associated pneumonia; ICU, intensive care unit.
a Data are presented as numbers (percentages) or means
 standard deviation unless otherwise indicated.
HCAP and PDR pathogens 1315with PDR pathogens. We assigned points as follows based on
the logistic regression: 5 points for nasogastric tube
feeding; 3 points for recent hospitalization within 90 days
of diagnosed pneumonia; 2 points for intravenous antibi-
otics within 30 days of diagnosed pneumonia; and 1 point
each for residence in a nursing home or extended-care
facility, chemotherapy or wound care within 30 days of
diagnosed pneumonia, or undergoing chronic dialysis.
Patients were divided into three groups by total scores.
Fig. 2 shows the association between total score using the
new scoring system and the prevalence of PDR pathogen
infections. As scores increased, the prevalence of PDR
pathogens in each group also increased (21.1% in the group
with a score of 0e2, 45.3% in the group with a score 3e5,
and 67.8% in the group with scores 6). Fig. 3 compares
ROC curves between the new scoring system and estab-
lished HCAP criteria. The area under curve (AUC) of the
new scoring system (AUCZ 0.711; 95% CI, 0.66e0.76) was
significantly higher than that of the current HCAP criteria
(AUCZ 0.634; 95% CI, 0.58e0.69) (P< 0.001). When the
total score of three points was established as the cut-off
points, the sensitivity, specificity, PPV, and NPV of this
Table 5 Association of HCAP risk factors and PDR pathogens.a
Risk factors PDR Non-PDR P-value Multivariate analysisb
Odds ratio 95% CI P-value
Hospitalization for 2 days
in the preceding 90 days
73 (59.8) 69 (31.8) <0.001 2.51 1.36e4.63 0.003
Residence in a nursing home
or extended-care facility
14 (11.5) 13 (6.0) 0.073 1.23 0.47e3.21 0.670
Intravenous antibiotic
treatment within 30 days
of pneumonia
30 (24.6) 16 (7.4) <0.001 2.35 1.04e5.29 0.039
Chemotherapy within 30 days
of pneumonia
15 (12.3) 31 (14.3) 0.607 0.64 0.26e1.57 0.334
Wound care within 30 days of
pneumonia
1 (0.8) 0 (0) 0.360 e e e
Hemodialysis clinic 7 (5.7) 6 (2.8) 0.237 2.91 0.88e9.63 0.081
Immunosuppression 37 (30.3) 53 (24.4) 0.237 1.48 0.76e2.90 0.250
Nasogastric tube feeding 19 (15.6) 3 (1.4) <0.001 15.28 4.15e56.28 <0.001
HCAP, health care-associated pneumonia; PDR, potentially drug-resistant; CI, confidential interval.
a Data are presented as numbers (percentages) or means standard deviation unless otherwise indicated.
b HosmereLemeshow goodness-of-fit, PZ 0.803.
1316 S.C. Park et al.new scoring system were 68.0% (95% CI, 60.7e74.7), 67.3%
(95% CI, 63.2e71.0), 53.9% (95% CI, 48.1e59.2) and 78.9%
(95% CI, 74.1e83.3), respectively.Figure 1 The percentages of PDR pathogens identified in
patient groups with different numbers of risk factors for HCAP.
The prevalence of PDR pathogens was 22.4% in the patient
group that possessed no risk factors, 42.9% in the group with
one risk factor, 52.7% in the group with two risk factors, and
75.0% in the group with three risk factors. PDR, potentially
drug-resistant; HCAP, health care-associated pneumonia.Discussion
This retrospective analysis shows that a significantly large
proportion of HCAP is associated with non-PDR pathogens
(51.5%). Moreover, each criterion defining HACP does not
carry equivalent risk for infection with PDR pathogens, andFigure 2 The percentages of identified PDR pathogens in
three different risk groups, determined using the new scoring
system. The prevalence of PDR pathogens was 21.1% in the
group with predictive scores ranging from 0 to 2, 45.3% in the
group with scores ranging from 3 to 5, and 67.8% in the group
that scored 6 or more. PDR, potentially drug-resistant.
Figure 3 Comparison of ROC curves between the new scoring
system and the currently employed HCAP criteria. The AUC of
the new score system (AUCZ 0.711; 95% CI 0.66e0.76) was
significantly larger than that of currently accepted HCAP
criteria (AUCZ 0.634; 95% CI 0.58e0.69) (P< 0.001). ROC,
receiver operating characteristic; HCAP, health care-
associated pneumonia; AUC, area under curve.
HCAP and PDR pathogens 1317the current HCAP criteria poorly predict which patients will
be infected with PDR pathogens. Therefore, further risk
stratification for PDR pathogens would provide better
identification of patients infected with these pathogens.
Our study showed that previous antibiotics treatment,
recent hospitalization, and nasogastric tube feeding were
significant predictors of PDR pathogens.
Several studies have reported the bacterial etiology of
HCAP. Similar to current findings, MRSA and P. aeruginosa
were most common in patients with HCAP.2,4,6 However, in
other studies, S. pneumoniae and Haemophilus influenzae
were the most common pathogens in HCAP.3,5,14 This differ-
ence of bacterial etiology among studies makes it difficult to
decide how to treat HCAP patients, especially whether we
should use broad-spectrum antibiotics empirically for all
HCAP patients. Current ATSeIDSA guidelines recommend
that broad-spectrum antibiotics should be considered as
initial treatment for HCAP patients. Although antibiotics
treatment according to ATSeIDSA guidelines would diminish
inadequate treatment, at the same time, it would heavily
increase overtreatment. Moreover, recent studies reported
that guideline-concordant HCAP therapy is not associated
with decreased mortality or hospitalization duration versus
guideline-concordant CAP therapy for HCAP patients.15,16
The HCAP criteria used in previous studies are diverse
and some differ from ATSeIDSA guidelines. Recent hospi-
talization was most commonly used, but the interval
between prior hospitalization and current infection varied
from 30 to 180 days.2e6,10,14,17 ATSeIDSA guidelines do not
include immunosuppression as a risk factor for HCAP, but
other studies frequently include it.3,4,6,10,17 In addition,
few studies exist concerning pneumonia in patients under-
going chronic dialysis, and it seems to be included as a risk
factor for HCAP more by convention than by scientific
evidence.18 The lack of consistency in defining HCAPimplies that current HCAP criteria are insufficient to
accurately predict patient infected with PDR pathogens,
and the empirical use of broad-spectrum antibiotic therapy
may result in overtreatment.
Previous studies evaluated risk stratification in HCAP for
identifying patients with drug-resistant pathogens.
Schreiber et al.,6 studied pneumonia complicated by
respiratory failure requiring mechanical ventilation and
found that the HCAP definition performed poorly in
detecting patients with resistant pathogens, achieving
a sensitivity of 78.3% and specificity of 56.2%. A multivar-
iate model identified immunosuppression, nursing home
residence, and prior antibiotic use as independent predic-
tors of infection with resistant pathogens. They assigned
different point values for each variable and developed
a clinical scoring tool to identify persons with resistant
pathogens. As the score increased, the frequency of PDR
infection increased. The sensitivity and specificity of this
scoring system were improved to 80.5% and 63.3%,
respectively. Similarly, Shorr et al.,10 found that the broad
HCAP definition had a sensitivity of 86.9% but a specificity
of only 48.6%. In the multivariate analysis, they found that
recent hospitalization, nursing home residence, hemodial-
ysis, and intensive care unit admission were independently
associated with patient infected with resistant pathogens.
A scoring system employing these four variables increased
accurate identification of patients with pneumonia caused
by resistant pathogens.
Consistent to previous reports, our study also shows that
the current definition of HCAP is too broad and its predic-
tive strength for patient infection with PDR pathogens
remains insufficient. HCAP patients comprise a heteroge-
neous group, and a significant number of these individuals is
not actually at risk for infection with PDR pathogens. Thus,
we need to also consider other individual factors in patients
with HCAP, such as a higher frequency of aspiration pneu-
monia and poor respiratory function, as predictors of
susceptibility to infection with PDR organisms.5 Impor-
tantly, the current study demonstrated that nasogastric
tube feeding is a significant risk factor that is strongly
associated with patient infection with PDR pathogens.
Nasogastric tube feeding implies poor condition of patient
and risk of silent aspiration because these patients are
generally in bedridden status and sustained opening of the
gastroesophageal junction occurs in patients with Levin
tube. According to previous studies, pseudomonas infection
or microbial colonization is more frequent in patients with
bronchiectasis.19,20 However, chronic lung disease including
bronchiectasis is not associated with PDR pathogens in this
study because other risk factors such as previous antibiotics
use and prior hospitalization may be more important for the
infection with PDR pathogens. In addition, immunosup-
pression was not a significant risk factor for PDR pathogens
in our study. Several previous studies have also reported
that immunosuppressive status was not significantly
different between CAP and HCAP and it was not a signifi-
cant risk factor for PDR pathogens.2,5 This finding suggests
that other individual factors besides those included in the
current HCAP criteria require identification. The current
definition of HCAP has poor diagnostic accuracy in
predicting infection susceptibility with drug-resistant
pathogens, and results in the excessive use of empirically-
1318 S.C. Park et al.selected antibiotics. Overall, this overtreatment not only
increases the frequency of adverse health events and
elevates health care costs, but also contributes to the
ongoing crisis of bacterial resistance to antibiotics.
Several limitations exist in the present study. First, this
was a retrospective study of patients admitted to a single
hospital. Patient selection bias might have influenced this
study, and our findings may not apply to other institutions.
Although previous studies have reported CAP is more
common than HCAP,2,3,5 our study showed a similar
proportion between CAP and HCAP patients. Two studies
which were conducted in the university affiliated tertiary
referral hospital in South Korea also showed a similar
proportion.21,22 We identified PDR pathogens in 34% of
total pneumonia patients. This proportion of resistant
pathogens is similar to another study that evaluated
pneumonia patients with respiratory failure.6 Moreover,
we included only patients with pneumonia that required
hospitalization, and they were older than the general
population and had higher rates of comorbidity. There-
fore, scoring tool in this study should be validated in the
larger scaled studies and physicians should consider the
characteristics of their local patient population when
deciding whether to apply our diagnostic approach at their
institution. Second, we analyzed only patients with
culture-positive pneumonia. Culture-negative results
constitute a significant proportion of pneumonia cases.
However, we analyzed only the culture-positive data
because we aimed to evaluate HCAP criteria for predicting
PDR pathogen infections. Third, our sample size and study
duration should be increased in follow-up studies. Patient
numbers in several groups such as nursing home residence
or hemodialysis were less than optimal. Pneumonia is
a serious complication in patients residing in a nursing
home or being on chronic dialysis and these patients have
poor clinical outcomes.23,24 A significant association
between these parameters and infection with PDR path-
ogens may be revealed when larger numbers of patients
are analyzed. In the case of the nursing home residing
group, however, increasing cohort size may not reveal this
criterion to be a key predictive risk factor, simply due to
the relatively scant utilization of nursing homes in South
Korea compared to other countries.21,22
In conclusion, infection with PDR pathogens is
common in patients with pneumonia acquired outside of
the hospital. Although HCAP patients have a greater risk
to be infected with PDR pathogens, each risk factor for
developing HCAP does not carry equivalent importance.
The current HCAP criteria are poor predictors of the
specific PDR pathogens that infect these patients, and all
patients with HCAP should not be empirically treated for
these pathogens using broad-spectrum antibiotic
therapy. Our data strongly suggest that the excessive and
inappropriate use of antibiotics can be reduced in
pneumonia patients by optimized and individualized risk
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